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Evolution of bacteria towards resistance to antimicro-
bial drugs, including multidrug resistance, is unavoidable
because it represents a particular aspect of the general
evolution of bacteria that is unstoppable. Therefore, the
only means of dealing with this situation is to delay the
emergence and subsequent dissemination of resistant bac-
teria or resistance genes. Resistance to antimicrobial drugs
in bacteria can result from mutations in housekeeping
structural or regulatory genes. Alternatively, resistance can
result from the horizontal acquisition of foreign genetic
information. The 2 phenomena are not mutually exclusive
and can be associated in the emergence and more efficient
spread of resistance. This review discusses the predictable
future of the relationship between antimicrobial drugs and
bacteria.
O
ver the last 60 years, bacteria and, in particular, those
pathogenic for humans have evolved toward antimi-
crobial drug resistance. This evolution has 2 key steps:
emergence and dissemination of resistance.
Humans cannot affect emergence because it occurs by
chance and represents a particular aspect of bacterial evo-
lution. Emergence can result from mutations in housekeep-
ing structural or regulatory genes or from acquiring foreign
genetic information. However, much can be done to delay
the subsequent spread of resistance. Dissemination can
occur at the level of the bacteria (clonal spread), replicons
(plasmid epidemics), or of the genes (transposons). These
3 levels of dissemination, which coexist in nature, are not
only infectious but also exponential, since all are associat-
ed with DNA duplication. Clonal dissemination is associ-
ated with chromosome replication, plasmid conjugation
with replicative transfer, and gene migration with replica-
tive transposition (1). The spread of resistance has repeat-
edly been shown to be associated with antimicrobial drug
use (2), which stresses the importance of the prudent use of
these drugs; a notion reinforced by the observation that
resistance is slowly reversible (3,4).
Therefore, attempting to predict the future of the rela-
tionship between antimicrobial drugs and bacteria is con-
ceptually challenging and potentially useful. For the sake
of convenience, the examples will be taken mainly from
the work carried out in the author’s laboratory, although
numerous other examples can be found in the literature. 
The clinically relevant predictable resistance types are
listed in the Table. Although they have not yet been report-
ed, they may exist in nature; their apparent absence is, at
least for some of them, rather surprising. For example,
streptococci, including pneumococci and groups A, C, and
G, can easily acquire in vitro conjugative plasmids from
enterococci and stably maintain and phenotypically
express them (5). Therefore, it is all the more surprising
that genes commonly found on plasmids in the latter bac-
terial genus, such as bla for penicillinase production and
aac6′-aph2″ for resistance to nearly all commercially
available aminoglycosides, have not yet emerged in strep-
tococci. The situation is even more unusual for Listeria
spp., which remain susceptible to most antimicrobial drugs
even though they can acquire plasmids from both entero-
cocci and staphylococci (6). However, the obligate intra-
cellular existence of Chlamydia spp. likely protects them
from contact with foreign DNA and accounts for their
retained susceptibility to antimicrobial drugs.
How To Anticipate Resistance
One should distinguish “natural” antimicrobial drugs
(e.g., kanamycin), which are produced by microorganisms
from the environment, from semisynthetic (e.g., amikacin)
and entirely synthetic compounds (e.g., quinolones),
which are produced, at least in part, by humans. The
microorganisms that produce natural antimicrobial drugs
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*Institut Pasteur, Paris, France 1Niels Bohr.have to protect themselves from the products of their own
secondary metabolism. To ensure their survival, these
organisms have developed self-protection mechanisms
similar to those found in resistant human pathogens (7);
this observation led to the idea that the producers consti-
tute the pool of origin of certain resistance genes (8).
Therefore, the study of resistance in the strain used for the
industrial production of an antimicrobial agent could allow
a strong prediction about the mechanism that will be found
later in bacteria pathogenic for humans. For example, the
study of glycopeptide producers would have allowed the
elucidation, long before it actually occurred, of the mech-
anism by which enterococci and, more recently, staphylo-
cocci could become resistant to these drugs (Figure 1).
As already noted, bacteria are resistant to antimicrobial
drugs after horizontal DNA transfer or mutations. Thus,
another prediction that can be made is that bacteria will
transfer to susceptible species, resistance determinants
already known in other bacterial genera, for example, the
recent acquisition of glycopeptide resistance by
Staphylococcus aureus from  Enterococcus spp. (9).
However, this prediction is limited since it refers to mech-
anisms that have already been explained. In addition to
being antimicrobial agent producers, the commensal bacte-
ria of mammals, particularly those in the gut, also repre-
sent a pool of origin for resistance genes. When infections
are treated with an antimicrobial agent, all bacteria in the
host are affected, including the commensal flora, which
could result in the selection of resistant commensals, par-
ticularly in children who are administered oral antimicro-
bial drugs too frequently. Large numbers of these resident
bacteria are present in the digestive tract where they are
often in transient, but intimate, contact with exogenous
microorganisms that are in various developmental states,
including competence. These conditions favor the transfer
of genes by transformation and by conjugation. Including
antimicrobial drugs in animal feed also leads to the selec-
tion of a pool of resistance genes that can be transferred to
commensal bacteria in the human digestive tract and thus
ultimately to human pathogens, even when selective pres-
sure is absent (10).
In the case of mutations, predictions can be supported
by 2 types of experimental approaches: in vivo with intact
bacteria or in vitro by using DNA. Mutations resulting in
resistance can be obtained in an accelerated fashion by
using hypermutators, that is, bacteria deficient in the DNA
repair system (11). Mutations are also accumulated by
using continuous cultures, preferably in chemostats under
suitable selective pressure. Asimilar enhanced rate of evo-
lution can be obtained by (saturated) DNA mutagenesis,
followed by transformation into an appropriate host. This
technique, for example, was used successfully to study the
extent of variations in penicillinase genes that generate
extended-spectrum β-lactamase agents (12).
Pathways to Resistance
Modulation of Gene Expression 
In addition to developing mutations in structural genes
for drug targets, bacteria can become resistant after muta-
tional events in motifs for gene expression, such as pro-
moters (13), in regulatory modules, such as 2-component
regulatory systems (14), or positioning upstream from a
gene of a mobile (15,16) or stable (17) promoter. Enhanced
expression of genetic information can also be caused by
alterations in translation attenuation (18). The DNA
regions involved in gene regulation are not always adja-
cent to the target gene. This factor makes finding regulato-
ry mutations more complicated and makes detecting
resistance by this mechanism generally impossible by
genotypic techniques (19).
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Figure 1. Comparison of the van gene cluster from the glycopep-
tide producer Streptomyces toyocaensis (32) and of the vanA
operon (33) from gram-positive cocci. Open arrows represent cod-
ing sequences and indicate direction of transcription. The guano-
sine plus cytosine content (% GC) is indicated in the arrows. The
percentage of amino acid (aa) identity between the deduced pro-
teins is indicated under the arrows.Dissemination by Transformation 
Dissemination by transformation is more likely in
spontaneously transformable bacterial species such as
Streptococcus pneumoniae,  Acinetobacter  spp., and
Neisseria spp. These bacteria can easily acquire, integrate,
and express stretches of DNA. Since the latter can include
portions of foreign chromosomes, this process renders
chromosomal mutations infectious (20).
Combination of Mechanisms 
Because of increased activity or the expanded spectrum
of certain drug classes (e.g., β-lactam agents and fluoro-
quinolones) or of local therapy (e.g., extremely high con-
centrations in the gut after oral administration of
glycopeptides that do not cross the digestive barrier) bac-
teria need to combine mechanisms that confer resistance to
the same class of molecules. This process is necessary to
achieve high-level resistance (21) or expand the substrate
range provided by a single resistance mechanism (22). An
example is provided by gram-negative bacteria and β-lac-
tam agents. Extended-spectrum β-lactamase agents are
point mutants of “old” penicillinases (23). Generally, the
biologic price to pay for extending the substrate range of
this enzyme is hypersusceptibility to β-lactamase
inhibitors. However, the presence in certain enterobacteria
of the gene for a penicillinase on a small multicopy plas-
mid, which results in production of large amounts of the
enzyme and confers resistance to β-lactamase inhibitors by
trapping (24). The net result of this combinatorial
approach is the production of gram-negative bacteria that
are resistant to all β-lactam agents, except carbapenems
and cephamycins, which are not substrates for the
enzymes.
Two Mechanisms Involved in Resistance 
Are Increasingly Frequent 
Impermeability
No antimicrobial agent is active against all bacteria. In
fact, the intrinsic (natural) resistance of bacteria, which is
better designated as insensitivity, defines the spectrum of
activity of a drug, usually because the antimicrobial drug
does not penetrate the bacteria. However, microorganisms
can become resistant to nearly all drug classes, including
those that act at the surface of the bacteria (e.g., β-lactam
agents, bacitracin), by impermeability. This resistance can
be secondary to 2 distinct pathways: passive, which
involves alterations of outer membrane proteins, the
porins, which decrease the rate of entry of antimicrobial
drugs into the bacteria by diminution of the pore size (25),
and active, which involves overexpression of an indige-
nous efflux pump that exports the antimicrobial drug out-
side the cell after a regulatory mutation (26).
Trapping
The mechanism of trapping, already mentioned in the
case of resistance to β-lactam agents by a combination of
β-lactamases, allows titration of the drugs, an alternative to
impermeability, for lowering the intracellular concentra-
tions of the antimicrobial drugs. This mechanism also
works against aminoglycosides in bacteria that overpro-
duce an enzyme that has affinity for a drug they cannot
inactivate since it lacks the modification site (Figure 2)
(27,28). This mechanism has also been proposed to account
for low-level resistance to glycopeptides in staphylococci
by overproducing target sites in the outer layers of the pep-
tidoglycan; thus, the antimicrobial drug does not reach the
important target sites where the wall is assembled on the
outer surface of the cytoplasmic membrane (29).
Prediction at the Genetic Level 
Genes from gram-positive cocci can be transferred by
conjugation (of plasmids or transposons) not only among
these microorganisms but also to gram-negative bacteria
(30). The reverse is not true because of limitations in het-
erologous gene expression. Consequently, one can confi-
dently predict further dissemination of the resistance gene
pool of gram-positive to gram-negative bacteria. 
We have been aware for a long period that “everything
that exists in the universe is the result of chance and neces-
sity” (Democritus, 460–370 BC), which holds true for
antimicrobial drug resistance. Most unfortunately, and for
various reasons, it is extremely difficult to think like a bac-
terium. In other words, predicting the emergence of resist-
ance to a drug class by a precise molecular mechanism is
nearly impossible (e.g., glycopeptide resistance in entero-
cocci or plasmid-mediated resistance to fluoroquinolones).
We also cannot anticipate, among all the conceivable
mechanisms of resistance (31), which will emerge first
under natural conditions. However, based on the under-
standing during recent decades of the physiology (genetics
and biochemistry) of bacterial resistance to antimicrobial
drugs, impressive progress has been made in the tech-
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Figure 2. Disk susceptibility test results of Escherichia coli BM694
(left) and of strain BM694 harboring plasmid pAT346, which con-
fers tobramycin resistance by trapping (right) (27).niques for in vitro detection and for elucidation of resist-
ance. This progress should, in turn, be helpful in delaying
the second step of resistance: dissemination.
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